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ABSTRACT 
Protein tyrosine phosphatases (PTPs) are important redox regulated enzymes that 
control the tyrosine phosphorylation status in the cell. These studies aimed to 
increase the understanding on how PTPs are controlled by reversible oxidation in 
different pathological settings such as hypoxia and restenosis and to which extent 
oxidized PTPs contribute to certain diseases.  
 
Low levels of oxygen - hypoxia - can occur in tumors due to poor vascularization as 
well as in myocardial infarction and is associated with increased levels of reactive 
oxygen species (ROS). In our study we found that hypoxia followed by reoxygenation 
caused reversible oxidation of PTPs. This created an increased amount of inactivated 
PTPs and was followed by prolonged PDGF receptor activation. The hypoxia induced 
increase in phosphorylation lead to elevated ERK signaling as well as increased 
formation of cytoskeletal re-arrangements which could be inhibited by addition of the 
antioxidant N-acetylcysteine. Decreased phosphatase activity was also seen when 
analyzed in heart tissues from an ex-vivo model of rat heart exposed to ischemia-
reperfusion.  
 
Atherosclerosis is a disease characterized by artery wall thickening due to a buildup of 
fatty materials. A common treatment is to open up the vessel with a balloon catheter 
and thereby increase the blood flow. A problem with this treatment is that restenosis 
occur after some time. Restenosis is associated with an elevated ROS production and 
increase in PDGFβ-receptor signaling. Using a rabbit restenosis model we could show 
that restenosis could be attenuated by administration of antioxidants. Tissue analysis 
from vessels in combination with cell culture experiments showed that the beneficial 
effect of antioxidant treatment was prevention of PTP inactivation.    
 
Peroxidized lipids have been found in increased amounts in several diseases with 
inflammatory components, like atherosclerosis and diabetes. The amounts of 
peroxidized lipids are tightly regulated by the glutathione peroxidase 4 (GPx4). In an 
inducible knock out model of GPx4 in cells we found that the rapid accumulation of 
peroxidized lipids caused PTP oxidation and lead to increased cell signaling. This was 
the first time peroxidized lipids were shown to oxidize and inactivate PTPs. 
 
PTPs are often regarded as inhibitors of cell signaling and therefore as potential tumor 
suppressors. SHP-2 is however, an exception and is a bona fida oncogene in which 
phosphatase-activating mutations have been associated with different forms of 
leukemia and to a smaller proportion with solid tumors. We found that PDGF-BB 
dependent growth of subcutaneous tumors was compromised when SHP-2 levels 
were repressed by shRNA. Cell culture experiments indicated that compromised Src 
activity and reduced ERK activation underlie the inability of these cells to form tumors. 
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1 INTRODUCTION 
 
1.1 TYROSINE PHOSPHORYLATION AS A CONTROL MECHANISM FOR 
CELL SIGNALING PROCESSES 
Phosphorylation of proteins is a regulatory mechanism that plays an important role in 
cellular processes such as proliferation, migration, differentiation, fertilization, 
apoptosis and metabolism. Phosphorylation is the covalent binding of the energy rich 
phosphate group (PO4) to a protein. Three amino acids that can be phosphorylated 
are serine, threonine and tyrosine. Serine phosphorylation is most abundant, whereas 
tyrosine phosphorylation represents only a small fraction of the total protein 
phosphorylation.  
    
The first tyrosine kinase (TK) was discovered over 30 years ago by Tony Hunter and 
colleagues (Eckhart et al 1979) and since then TKs have been shown to participate in 
many signaling processes (Lemmon and Schlessinger 2010). Receptor tyrosine kinases 
(RTKs) are trans-phosphorylated at different sites when ligand stimulated. These 
phosphorylated sites recruit other proteins which in turn, in some cases, also become 
phosphorylated and thereby promote the downstream signal transduction of RTKs. 
The phosphorylation status is strictly regulated to prevent uncontrolled signaling, 
which otherwise can give rise to diseases such as cancer (Brognard and Hunter 2011).  
 
Approximately one decade after the first TK was found, Edmond Fisher and colleagues 
purified the first protein tyrosine phosphatase (PTP) (Tonks et al 1988).  PTPs have 
since then been shown to regulate many signaling processes (den Hertog et al 2008, 
Ostman et al 2006, Tonks 2006). As the name suggests, the PTPs dephosphorylate 
tyrosine-phosphorylated proteins. Individual PTPs display specificity for certain 
substrates, and in some cases also to specific phospho-tyrosine sites, and thereby 
contribute to a precise fine-tuning of the receptor signal (Ostman and Bohmer 2001). 
PTPs thus act as important regulators of RTK signaling. 
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1.2 THE PTP FAMILY 
The PTP family consists of 107 PTPs encoded by the human genome. Two major 
subgroups are the dual specificity phosphatases that dephosphorylate serine, 
threonine and tyrosine, and the phosphotyrosine-specific PTPs. The first PTP to be 
purified and cloned was PTP-1B (Charbonneau et al 1989, Guan et al 1990, Tonks et al 
1988). Since then, 37 additional classical phosphatases have been found. The classical 
PTPs can be further divided into receptor PTPs (RPTPs) and non receptor PTPs 
(NRPTPs) which consist of 17 and 21 members, respectively (Fig 1.) (Alonso et al 
2004).  
 
Figure 1.  Schematic representation of some of the classical PTPs 
The left part of the illustration shows representative RPTPs. RPTPs contain a membrane spanning region 
and an extracellular domain which often contains domains involved in cell adhesion, such as 
immunoglobulin-like, fibronectin-III-like repeat, or MAM domains. The RPTPs also contain one or two 
intracellular PTP domains. The right part displays some NRPTPs which consist of one single PTP domain 
and often domains involved in protein-protein interactions such as SH2, FERM and PDZ domains (Figure 
adopted from (Ostman et al 2006)). 
 
All the classical, phosphotyrosine specific PTPs, contain a 240–250 amino acid PTP 
domain with an active site sequence. In addition to the catalytic domain they contain 
many different regulatory domains or motifs which make the PTPs a diverse group of 
proteins. The RPTPs contain a transmembrane α-helix which directs them to the 
plasma membrane and an extracellular part that allows the transfer of signals through 
the membrane. The NRPTPs contain many protein-protein interacting domains, e.g. 
the Src homology 2 (SH2) domain of SHP-1 and SHP-2, that directs them to their target 
proteins as well as regulating their enzymatic activity. Some of the NRPTPs also 
contain sequences targeting them to the sub-cellular locations, e.g. the endoplasmatic 
reticulum-targeting (ER) sequence of PTP1B (Alonso et al 2004). 
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1.2.1 Regulation of PTPs  
Reversible oxidation of the active site cysteine causes an inactivation of the catalytic 
activity of PTPs, and is a major regulatory mechanism which is described in more 
detail below (section 1.4) (Salmeen and Barford 2005). 
 
Dimerization  
Dimerization of RPTPs can lead to inactivation of the enzymatic activity as has been 
described for RPTPα (Bilwes et al 1996). Dimerization-induced inhibition of PTPRO 
activity was also demonstrated when a chimeric fusion protein was analyzed (Hower 
et al 2009). In contrast, activating dimerization of DEP-1 has been seen. Using an 
antibody against DEP-1, Takahashi et al could detect an increased DEP-1 activity, 
which also reduced intracellular signaling and blocked proliferation. When the 
antibody was used in mice, corneal angiogenesis was decreased. The effects were not 
seen when a monovalent form of the antibody was used (Takahashi et al 2006).    
 
Ligand induced regulation  
Ligand induced regulation of RPTPs can occur. One example is pleiotrophin that causes 
a reduction of the RPTP β/ζ catalytic activity (Meng et al 2000). RPTPs are important 
for development in neuronal synapses. In a Drosophila model, syndecan (a heparan 
sulfate proteoglycan) has been shown to bind to PTP-LAR and increase signaling (Fox 
and Zinn 2005). In another Drosophila model of synapse development, a different 
heparan sulfate proteoglycan, dallylike, had opposite effects on LAR signaling (Johnson 
et al 2006). 
 
Phosphorylation 
Phosphorylation is a common modification of PTPs leading to different effects on the 
catalytic activity of PTPs. 
 
PTP1B has been shown to be inactivated by insulin in an Akt dependent manner, due 
to serine-phosphorylated residues in the catalytic site (Ravichandran et al 2001). 
Insulin stimulation in vivo could also inactivate PTP1B, involving tyrosine 
phosphorylation (Tao et al 2001). However, increased activity of PTP1B has also been 
found due to EGF-induced tyrosine phosphorylation, which created binding to Grb-2 
(Liu and Chernoff 1997) . 
 
RPTPα was found to be serine phosphorylated (Tracy et al 1995) which increased the 
catalytic activity (den Hertog et al 1995). In contrast, another study showed that 
RPTPα serine dephosphorylation by PP2A increased the ability of  RPTPα to 
dephosphorylate Src on its inhibitory phosphorylation site (Vacaru and den Hertog 
2010). Also tyrosine phosphorylation has been found on RPTPα. The tyrosine 
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phosphorylation was concluded to be essential for the binding and dephosphorylation 
of Src (Zheng et al 2000).  
 
RPTPs have also been shown to dephosporylate each other. Both CD45 and RPTPα 
regulate Src family kinases (SFKs), but the expression pattern of the two RPTPs is 
different. CD45 is the major PTP expressed in T-cells whereas RPTPα is more widely 
expressed but can also be found in T-cells. When analyzing T-cells without CD45, 
RPTPα phosphorylation was increased, indicating that RPTPs can cross-talk and 
regulate each other (Maksumova et al 2007).  
Platelet derived growth factor (PDGF) and fibroblast growth factor (FGF) receptor 
stimulation has been found to phosphorylate SHP-2 on tyrosine residues (Feng et al 
1993, Vogel et al 1993). The tyrosine phosphorylation on SHP-2 was found to be 
required for the PDGF- and FGF-induced ERK activation. Nevertheless, mutation of the 
tyrosine residues on SHP-2 could not completely decrease the ERK activation (Araki et 
al 2003). Biochemical studies explained that tyrosine phosphorylation of SHP-1 and 
SHP-2 increases the catalytic activity, possibly through changes in intramolecular 
inhibition (Lu et al 2001, Zhang et al 2003). SHP-2 can also be serine phosphorylated in 
a manner not affecting catalytic activity (Strack et al 2002). 
 
Expression 
PTPs are differentially expressed both in different cell types and tissues. A recent 
study in immune cells showed that different immune cell lineages had their own PTP 
expression signature, probably affecting specific signaling pathways important for 
each cell lineage (Arimura and Yagi 2010). Increased expression of DEP-1, PTP-LAR, 
PTPµ, RPTPᴋ and PTPβ was seen in cells cultured at high densities (Campan et al 1996, 
Fuchs et al 1996, Gaits et al 1995, Longo et al 1993, Ostman et al 1994). PTP 
expression levels have also been shown to change during the pathological process of 
restenosis (Kappert et al 2007).  
 
Another mechanism that alters the PTP expression profile is the alternate usage of 
different promoters. This has been shown to give rise to tissue-specific forms of SHP-1 
(Banville et al 1995) and to different isoforms of RPTPԑ (Elson and Leder 1995). 
 
Proteolysis 
The extracellular parts of some RPTPs are cleaved, sometimes causing translocation of 
the intracellular PTP domain to distinct cellular locations (Aicher et al 1997, Jiang et al 
1993, Streuli et al 1992).  The cleavage can be a consequence of high cell density and 
has been described for PTPmu (Campan et al 1996). Cleavage due to high cell density 
has also been shown for RPTPκ. The resulting intracellular PTP-containing domain can 
translocate to the nucleus and dephosphorylate β-catenin (Anders et al 2006). Calpain 
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cleavage of PTP1B redirects the catalytical domain of PTP1B from the ER to the cytosol 
and increases its catalytic activity (Frangioni et al 1993). 
 
Subcellular localization 
The localization of PTPs in the cell is important, since that will determine access to 
their substrates. PTPs contain different localization signals, as described in section 1.2.  
This directs e.g. RPTPs to the cell membrane and PTPs with ER targeting sequences to 
the ER and a compartment specific regulation of tyrosine phosphorylation is thereby 
achieved.  
 
RPTPs are located in the membrane and have been found in complexes with TKs 
thereby regulate their signaling. Two examples are RPTP LAR in complex with TrkB 
(Yang et al 2006a) or together with c-Met (Machide et al 2006). 
 
Some PTPs contain sequences that direct them to the ER. PTP1B is one example and 
most of its activity is found in the peri-nuclear area (Frangioni et al 1992). The 
participation of PTP1B in dephosphorylation of RTKs might therefore be due to the 
internalization of RTKs in endosomes (Yudushkin et al 2007). TC-PTP on the other 
hand is subjected to alternative splicing that gives rise to two different isoforms 
containing different carboxy terminals, TC45 and TC48, localized to the nucleus and 
the ER, respectively (Lorenzen et al 1995). 
 
SH2 domains recognize and bind to phosphorylated tyrosine residue in a sequence-
specific way. Binding of SH2-domain proteins is important for initiating the 
intracellular signaling of RTKs (Manning et al 2002). The cytoplasmatic SHP-1 and SHP-
2, are recruited to cell surface proteins via their SH2 domain (Neel et al 2003). After 
ligand stimulation, SHP-2 has been shown to translocate to the activated PDGFβ 
receptors (Meng et al 2002). In addition to the SH2 domain, SHP-1 has a C-terminal 
motif that binds acidic phospholipids. This recruits SHP-1 to the cell membrane (Frank 
et al 1999)  and has been shown to regulate T-cell receptor signaling in T-lymphocytes 
(Sankarshanan et al 2007). SHP-1 has further been shown to have a nuclear 
localization signal and translocates to the nucleus after epidermal growth factor (EGF) 
stimulation (He et al 2005).  SHP-2 was first believed to be a cytosolic PTP but has also 
been found associated to STAT5 in the nucleus (Chughtai et al 2002).  
 
This spatial dissection of PTPs might allow proteins to stay phosphorylated and 
participate in signaling at a certain compartment. 
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1.3  IN VIVO FUNCTION OF PTPs  
Animal models have been generated to explore the in vivo function of PTPs. Nearly all 
members in the “classical” PTP family have been deleted in animal models by various 
techniques and some of them were found to be essential for life and therefore 
embryonic lethal when depleted (Hendriks et al 2008). SHP-2, PTP-PEST, VE-PTP and 
PTP-MEG2 null mice have been found to die during embryogenesis (Dominguez et al 
2007, Sirois et al 2006, Wang et al 2005, Yang et al 2006b).  
 
Generation of TC-PTP knock-out mice has shown that this knock out is not 
embryonical lethal. However, TC-PTP null mice died soon after birth. Analyses showed 
that TC-PTP is important for hematopoiesis and immune function (Heinonen et al 
2004, You-Ten et al 1997).  
 
Two mouse strains with different SHP-1 mutations have been described, the 
motheaten (me) and the viable motheaten (mev). Both mutations were found to be at 
the same gene but on different positions, creating a protein with differential 
deficiency (Green and Shultz 1975, Shultz et al 1993, Tsui et al 1993). The mev mouse 
with functionally deficient SHP-1 protein is viable and display enhanced insulin 
sensitivity compared to wild type (Dubois et al 2006). 
 
One study explained that DEP-1 null mice were viable (Trapasso et al 2006). However, 
another DEP-1 model, with a replaced intracellular domain, was shown to be 
embryonic lethal (Takahashi et al 2003). This might depend on the remaining 
extracellular domain that could participate in signaling and prevent vascular 
development.  
 
1.4 PTP OXIDATION  
Already in 1974, Czech et al showed that a component of the glucose transport system 
becomes sulfhydryl oxidized upon binding of insulin to cell surface receptors (Czech et 
al 1974). In 1988 Koshio at el showed an increase in insulin receptor phosphorylation 
after exogenous addition of H2O2 (Koshio et al 1988). Two years later it was shown 
that the increased phosphorylation was due to inactivated phosphatases (Heffetz et al 
1990). Since then, many studies have demonstrated inhibitory oxidation of the active 
site of different PTPs (Boivin and Tonks 2010, den Hertog et al 2008, Meng et al 2002, 
Salmeen et al 2003).  
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1.4.1 Maintenance of cellular redox balance  
The levels of reactive oxygen species (ROS) are balanced by the actions of synthesis of 
reactive oxygen species and antioxidant capacity to scavenge the ROS.  
 
Reduction of ROS can occur directly through H2O2 degrading enzymes (e.g. catalase, 
glutathione peroxidases or peroxiredoxins). Superoxide can be removed by superoxide 
dismutase (SOD) which exists in three different isoforms, the cytoplasmic SOD1, 
mitochondrial SOD2 and extracellular SOD (ecSOD). These SODs convert superoxide to 
H2O2 which can be converted to water by catalase or peroxidase (Chen et al 2009b).  
 
Cells have two major systems to maintain the cellular thiol-disulfide redox status, 
they are the thioredoxin (Trx)/thioredoxin reductase (TrxR) system and the 
glutathione (GSH)/glutaredoxin (Grx) system (Lillig and Holmgren 2007, Lillig et al 
2008).  
 
In addition, removal of ROS can be performed by treatment with cell-permeable 
antioxidants such as N-acetylcysteine (NAC). The ROS mentioned below mostly 
consists of H2O2, superoxide and the hydroxyl radical. 
 
1.4.1.1 ROS scavenging and reducing enzymes 
Low molecular weight antioxidants  
Glutathione and ascorbate are found at high concentration in cells where they are 
active against H2O2 and superoxide, respectively. Glutathione is a tri-peptide that 
consists of glutamate, cysteine and glycine, and is important both for protection 
against ROS and for maintaining ascorbate in the reduced state (Chen et al 2009b).  
 
Peroxiredoxins (Prxs)  
Prxs are believed to be the main converters of H2O2 to water. The Prxs exist as 
homodimers that gain intermolecular disulfide bonds in the H2O2 scavenging process 
and can be reduced by Trx. Oxidized Trx is then reduced by TrxR using NADPH as the 
electron donor (Chen et al 2009b).  
 
Both Prxs and PTPs contain a thiolate anion with a low pKa which makes them reactive 
with H2O2 at neutral pH.  A kinetic model system displayed that H2O2 was much more 
likely to react with PrxII than with PTP1B, taken in to consideration protein 
concentration and rate constants for both proteins (Winterbourn 2008). Nevertheless, 
it is clear that PTPs are inactivated by ROS produced by different stimulis. Explanations 
have been proposed to involve inactivation of Prx either through hyper-oxidation or 
phosphorylation of Prx, as discussed below. This might create sub-cellular 
compartments with transient accumulation of H2O2 leading to inactivated PTPs.  
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Reversibly oxidized Prx forms intermolecular disulfides that are reduced by Trx. This is 
a slow process and sometimes Prx is further oxidized to the hyper-oxidized sulfinic 
acid form. The sulfinic form of Prx can be reduced by sulfiredoxin (Woo et al 2003).  
 
Woo et al discovered that PrxI and PrxII are regulated by two different mechanisms. 
They found that PrxI was tyrosine phosphorylated after PDGF and EGF stimulation and 
that the phosphorylation decreased PrxI activity (Woo et al 2010). The 
phosphorylation of PrxI was further increased when NOX1 was over-expressed. EGF 
stimulation was shown to induce co-localization of NOX1 and phosphorylated PrxI in 
the cell membrane. To study the role of PrxI phosphorylation in vivo wound healing 
was investigated and found to be associated with increased PrxI phosphorylation, 
especially in the edge of the wounds where RTK signaling was also very active. The 
PrxI phosphorylation declined at the same rate as wound healing.  PrxII, on the other 
hand, was not tyrosine phosphorylated but found to be inactivated by hyper-
oxidation. This growth-factor-induced PrxI inactivation might be an important way to 
facilitate RTK signaling during certain circumstances.  
 
Glutathione peroxidase 4 (GPx4)  
GPx4 belongs to a family of 8 members. Embryos from GPx4 knockout mice die in 
early embryogenesis. GPx4 can reduce small hydroperoxides (e.g. H2O2), fatty acid 
hydroperoxides, cholesterol and complex membrane lipid hydroperoxides using 
glutathione as the electron donor (Conrad 2009). Depletion of GPx4 in cells has been 
shown to induce apoptosis due to an increased 12/15-lipoxygenase activity and 
concomitant generation of lipid hydroperoxides (Seiler et al 2008).  
 
1.4.1.2 ROS production 
The two main sources of ROS in the cell are the mitochondria and NADPH oxidases. 
 
Mitochondria and ROS production  
Cellular respiration is associated with ROS production (Rigoulet et al 2011). This is 
believed to predominantly occur in the “Q cycle” of complex III and involves 
superoxide production both at the inner and outer surface of the inner membrane. 
Another part of the respiratory chain that contributes to ROS production is complex I.  
 
The TCA cycle represents another mitochondrial source of ROS. Dehydrogenases such 
as alpha-ketoglutarate dehydrogenase and pyruvate dehydrogenase are implied as 
ROS generators. Furthermore, a series of studies have demonstrated that 
mitochondrial metabolism of lipids, including palmitoyl-carnitine, leads to ROS 
production independent of the respiratory chain (Rigoulet et al 2011).  
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Regulation of mitochondrial ROS production remains poorly characterized. However, 
“uncoupling” is recognized as one state associated with reduced ROS generation.   
 
As discussed in study II of this thesis, hypoxia and hypoxia/reoxygenation are 
associated with increased mitochondrial ROS production. In this context it can be 
noted that a recent study, using a redox-sensitive protein sensor (RoGFP), targeting 
different cellular localizations, showed that hypoxia caused increased ROS production 
in the intermembrane space of the mitochondria (Waypa et al 2010).  
 
NADPH oxidase (NOX) 
NOX is a membrane protein and catalyzes the transfer of electrons from nicotinamide 
adenine dinucleotide phosphate (NADPH) on the inside of the cell across the 
membrane. When electrons come in contact with oxygen on the outside superoxide 
or H2O2 are formed. 
 
Mammalian cells consist of five different NOX family members (NOX1, NOX2, NOX3, 
NOX4, or NOX5). Some of them require different subunits (p22phox, p47phox, 
p67phox and the small guanosine triphosphatase Rac1) to be activated although 
NOX5 exists as a monomer (Fig 2). Some subunits are common for some of the 
members, while others are isoform-specific. Therefore different NOX enzymes display 
difference in sub-cellular localization, tissue distribution and cellular functions (Chen 
et al 2009b). 
 
Figure 2. Schematic picture of representative NADPH oxidase members in endothelial cells (figure 
adopted from (Frey et al 2009)). 
 
Other sources of ROS 
There are also other sources of ROS in the cell. Glutamate, serum deprivation or UV 
irradiation are examples of ROS inducers.  Metabolism of drugs or xenobiotics has also 
been shown to produce ROS. Furthermore, anticancer drugs, like doxorubicin, react 
with cytochrome P450 which creates a radical that reacts with oxygen and generates 
superoxide (Winterbourn 2008). As discussed in studies III and V of this thesis, 
peroxidized lipids can also act as oxidizing agents. These are formed in the eicosanoid 
synthesis pathway which ultimately converts arachidonic acid (AA) to eicosanoids. A 
key enzyme in this pathway is 12/15-LOX which oxygenates arachidonic AA or other 
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poly unsaturated fatty acids (PUFAs). The main product from 12/15-LOX derived AA 
oxidation is hydroperoxyeicosatetraenoic acid (15-HpETE) (Kuhn and O'Donnell 2006).  
 
1.4.2 ROS as signal transducers 
For a long time ROS were believed to only have cytotoxic effects in e.g. phagocytotic 
cells and in neurodegenerative diseases. However, accumulating evidence indicate 
that ROS can also participate in cell signaling. In order for a particular ROS to function 
as a signaling molecule, it should not be too reactive, since the half-life will be too 
short to react with a target. An example is the hydroxyl radical (OH˙) which has a very 
short half-life. Superoxide and H2O2 on the other hand, have more favorable chemical 
profiles to function as signaling molecules. 
 
Superoxide (O2˙-) cannot diffuse through membranes because of its negative charge 
and therefore needs to be transported through anion channels. Superoxide dismutase 
converts superoxide to the two electron oxidant H2O2 that can easily diffuse through 
membranes. H2O2 can then react with protein thiols to produce different sulfur 
oxidation states, such as disulfides (S-S), sulfenic (-SOH), sulfinic (-SO2H) or sulfonic (-
SO3H) acid products. The first two are regarded as reversible post-transcriptional 
modifications that are important for cell-signaling (Chen et al 2009b). 
 
The first example of ROS as a signaling molecule after RTK stimulation came from 
Sundaresan et al. They found that treatment of cells with antioxidants such as catalase 
or NAC inhibited receptor phosphorylation and downstream signaling (Sundaresan et 
al 1995). Later the same group found that the small GTP-binding protein Rac1 created 
a significant increase in intracellular ROS. They also found that growth factors such as 
PDGF and EGF and cytokines like tumor necrosis factor alpha or interleukin could 
induce ROS formation in NIH3T3 cells (Sundaresan et al 1996). Subsequently, PI3K has 
been shown to be required for PDGF mediated ROS formation (Bae et al 2000).   
 
1.4.3 Biochemistry of PTP oxidation 
The PTP active site (VHCSAGxGR[T/S]G) contains a conserved cysteine residue with a 
low pKa value. Therefore, at physiologic pH, the catalytical cysteine is deprotonated 
which makes it a good nucleophile that actively participates in the dephosphorylation 
process. This also makes the cysteine easily react with ROS. Oxidation of the catalytic 
cysteine destroys the nucleophilic effect and the phosphatase activity is lost. The 
oxidation of the cysteine thiolate anion to sulfenic acid is a reversible process. Further 
exposure to ROS can convert the sulfenic acid to sulfinic- or sulfonic- acid forms that 
represent irreversible modifications (Fig 3.) (den Hertog et al 2005).   
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Figure 3. Protein tyrosine phosphatase regulation by reversible oxidation   
 
There appear to be mechanisms to protect PTPs from irreversible oxidation. In PTP1B 
and RPTPα a reversible sulfenylamide bond has been described between the 
oxidized cysteine and an adjacent serine residue (Salmeen et al 2003, van Montfort 
et al 2003, Yang et al 2007). Additional variants of oxidized PTPs have also been 
described, including catalytically inactive forms of SHP-2 containing a thiol-disulfide-
bridge between two cysteines, but not including the active site cysteine (Chen et al 
2009a). 
 
The normally occurring oxidized PTPs are believed to be reversibly oxidized and 
susceptible to reduction by e.g. glutathione or thioredoxin. Some early studies 
suggest that PTPs differ with regard to “reduction-susceptibility” and also that they 
display differential sensitivity to different reducing agents. A recent study showed that 
SHP-2 but not SHP-1 could be reactivated by thioredoxin (Chen et al 2009a), whereas 
another study showed that PTP1B could be re-reduced by thioredoxin but not by 
glutaredoxin (Lee et al 1998).  
 
Biochemical studies also suggest that PTPs differ in susceptibility to oxidation. Such 
examples include demonstrations of different oxidation sensitivity of the two PTP 
domains of RPTPα, as well as between SHP-1 and SHP-2 (Chen et al 2009a, Persson et 
al 2004, Weibrecht et al 2007). Furthermore, dual specificity protein phosphatases 
and lipid phosphatases differ with regard to oxidation susceptibility (Ross et al 
2007). Finally, analyses of transfected PTPs and recombinant GST-PTP fusion 
proteins also uncovered big variations in oxidation susceptibility (Groen et al 2005, 
Persson et al 2004).  
 
1.4.4 Control of GF signaling by ROS regulators  
Lee et al showed that EGF stimulation of cells caused inactivation of PTP1B. The 
inactivation was transient, greatest 10 minutes after addition of EGF and returned to 
base line after 40 minutes (Lee et al 1998).  Insulin can also cause a reversible 
oxidative inhibition of PTPs, including TC-PTP and PTP1B (Meng et al 2004). Transient 
   17 
inhibition has also been seen in SHP-2 after PDGF stimulation, but only in the pool of 
SHP-2 that was recruited to the PDGF receptor (Meng et al 2002).  
 
Also non-RTKs have been shown to induce inhibitory PTP oxidation. In anti-IgG 
stimulated B-lymphocytes an increased ROS production that inhibited SHP-1 has been 
observed (Singh et al 2005). Stimulation of antigen receptor of T cells caused transient 
oxidation of SHP-2. The oxidation of SHP-2 could be prevented by expression of PrxII 
or addition of antioxidants. By usage of the PrxII over-expressing cells they observed 
that prevention of SHP-2 oxidation led to increased adhesion (Kwon et al 2005). 
 
A pattern is thus emerging suggesting that stimulation of cells with growth factors 
induces production of ROS, which in turn oxidize and inactivate different PTPs that can 
no longer dephosphorylate the RTKs. However, cells have a very efficient machinery to 
maintain cellular redox balance. It is therefore puzzling how RTKs can mediate ROS 
induced inactivation on PTPs. Mechanisms, also discussed above in section 1.4.1 and 
1.4.2, that have been proposed to account for growth-factor-induced elevation of ROS 
are local inactivation of Prx and increased NOX activity (Fig 4). 
 
Figure 4. Mechanisms for growth-factor induced elevation of ROS levels 
Growth factor stimulation can activate PI3K which promotes Rac1 activation of NOX (Bae et al 2000). 
NOX can produce H2O2 or superoxide that is converted to H2O2 by SOD. Prx that normally scavenge H2O2 
can be inactivated by oxidation upon elevated levels of ROS (Woo et al 2003).  An alternative pathway 
for PrxI is the inactivating tyrosine phosphorylation (Woo et al 2010). An additional pathway, for PTP 
inactivation is production of peroxidized lipids from AA (data from study III and V). 
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The discussions above have emphasized growth-factor-induced PTP oxidation as a 
critical component of RTK signaling. A related, but distinct phenomena, is that growth 
factor responses are determined by the particular redox state of the target cell. This 
concept has received experimental support through a series of studies which have 
showed alterations in growth factor signaling in cells where expression levels of 
various redox enzymes have been perturbed. 
 
PTP1B activity has been shown to be inhibited by insulin stimulation. The inactivation 
of PTP1B  and the elevated insulin signaling cascade could be reverted by addition of 
catalase (Mahadev et al 2001).  Juarez et al showed that cells treated with a SOD1 
inhibitor decreased the amount of produced H2O2. This protected PTPs from oxidation 
and minimized the effects of growth factor stimulation (Juarez et al 2008). 
 
Cells over-expressing glutaredoxin (Grx) displayed a decreased response to PDGF 
stimulation both with regard to PDGF receptor phosphorylation and proliferation. 
Depletion of Grx induced the opposite effect. It was also shown that LMW-PTP acted 
as a PDGF receptor targeting phosphatase and that LMW-PTP was protected from 
oxidation in cells with Grx over-expression. In vitro studies revealed that LMW-PTP 
formed reversible oligomers after H2O2 stimulation, and that this could be prevented 
by the presence of Grx. However, Grx needed the glutathione regenerating system to 
inhibit the oxidation of LMW-PTP (Kanda et al 2006). 
 
Manipulations of NOX members have also been shown to affect growth factor 
signaling. Mahadev at al showed that NOX4 is important for insulin receptor signaling 
due to its ROS production that in turn inhibited PTP1B (Mahadev et al 2004). Another 
study showed that PTP1B was inhibited by ROS from NOX4, but only when both 
proteins were located in the ER. This was important for EGF signaling, since the EGF 
receptors that remained phosphorylated due to PTP1B inactivation, were recycled to 
the cell membrane instead of being degraded (Chen et al 2008). In a lens epithelial cell 
model Wang et al showed that p22phox (subunit of NOX) is involved in ROS production 
affecting LMW-PTP oxidation and PDGF receptor phosphorylation (Wang and Lou 
2009).  
 
Dual oxidase 1 (DUOX1) expression was found to be increased in epidermal 
keratinocytes after interleukin stimulation. The increased levels of DUOX1 protein was 
accompanied by increased H2O2 levels. The increased ROS production caused 
oxidation of PTP1B and increased phosphorylation of STAT6. DUOX knockdown or 
usage of a NOX inhibitor decreased the interleukin induced oxidation of PTP1B 
(Hirakawa et al 2011). Interleukin stimulation was also shown to, via NOX5, produce 
ROS which caused an increase in STAT 6 activation. PTP1B was the main PTP 
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responsible for the increased STAT6 signaling and was found to be oxidized from the 
interleukin stimulation (Sharma et al 2008). 
 
Focal complexes are formed prior to cell migration and are enriched in tyrosine 
phosphorylated proteins. The NOX subunit, p47phox, was also found to be enriched in 
these structures, and found to oxidize PTP-PEST (Wu et al 2005). 
 
1.4.5 Tissue based evidence for PTP oxidation 
A set of recent studies have also implicated ROS-induced PTP oxidation in in vivo 
models.  
 
One example is PrxII that was shown to be recruited to activated PDGF receptors 
where it attenuates the PTP oxidation and decreases PDGF receptor signaling in vitro.  
PrxII knockout mice also displayed increased thickening of the vessel wall compared to 
wild type mice in a model of restenosis, which is consistent with a negative role for 
PrxII in PDGF signaling through inhibition of PTP oxidation (Choi et al 2005).  
 
Mice lacking GPx1 showed increased ROS and increased PTEN oxidation.  The 
consequence was elevated intracellular signaling which created increased insulin 
sensitivity compared to wild type. Treatment with the antioxidant NAC attenuated the 
enhanced signaling and insulin sensitivity in the GPx1 knockout mice (Loh et al 2009).  
Oshikawa et al used a hind limb ischemia model to display increased angiogenesis 
when ecSOD was expressed. Cell culture studies revealed that the ecSOD increased 
oxidation of PTP1B and DEP-1 in caveolae lipid rafts which in turn increased the VEGF 
receptor signaling (Oshikawa et al 2010). 
 
As discussed below, study II and study IV also presents evidence for in vivo oxidation 
of PTPs in the context of tissue ischemia and in restenotic vessels.  
 
1.4.6 Methods for detecting oxidized PTPs 
Most methods that analyze PTP oxidation in cell lysates or tissues share two features. 
Firstly, they require that experiments are done under low or oxygen-free conditions, 
since PTPs are highly sensitive to oxidation induced by atmospheric oxygen. 
Experimental procedures therefore need to be performed under very low oxygen 
conditions using reagents that contain as little oxygen as possible. Secondly, most 
assays involve the differential reaction of a chemical with reduced and oxidized PTPs 
that will allow these two pools to be distinguished from each other. Most often this 
involves the reaction of the reduced active-site cysteine with alkylating agents, such as 
iodoacetic acid (IAA), which do not react with the oxidized cysteine.  
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Some studies analyzing PTP oxidation has relied on in vitro dephopshorylation assay, 
using pTyr-peptides as substrate. Assays, performed on total cell lysates or on 
immunoprecipitated PTPs, are done in the absence or presence of exogenously added 
reducing agents. The difference in activity observed under these conditions is 
assumed to reflect the fraction of oxidized PTPs. An intrinsic problem with this 
approach is the difficulty in controlling the experimentally induced PTP oxidation 
occurring during the analytical steps. 
 
The OxPTP assay is an antibody-based method for detection of oxidized PTPs (Persson 
et al 2004, Persson et al 2005). It uses an antibody recognizing a stable derivative of 
the oxidized PTP active site. In this assay all reduced PTPs are alkylated with iodoacetic 
acid during cell lysis. The PTP of interest is subsequently immunoprecipitated and 
subjected to pervanadate treatment which converts the oxidized active site cysteine 
to a sulfonic acid (SO3). This derivative is finally detected by immunoblotting using the 
designated oxPTP antibody, originally raised against a PTP active site peptide with the 
cysteine in its sulfonic acid form (Fig 5.). The assay has been used to detect oxidation 
of endogenous PTPs, when antibodies of sufficient quality were available, and 
epitope-tagged recombinant and transfected PTPs.  
 
 
Figure 5. oxPTP antibody based method for detection of oxidized PTPs (adopted from (Persson et al 
2004)) 
 
The In gel assay for PTP oxidation also uses initial alkylation of reduced PTPs as a 
strategy for counter-selection of the reduced variants. The reversibly oxidized PTPs 
are detected based on their ability, following renaturation, to dephosphorylate [γ-32P]-
labeled Glu4Tyr peptides integrated in an SDS-polyacrylamide gel (Meng et al 2002). 
This method has the disadvantage that oxidation of RPTPs are not properly detected 
since these large, membrane proteins do not properly refold in the gel. The assay has 
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been used to monitor oxidation of multiple PTPs, by analyses of total cell lysates, or of 
individual PTPs using immuno-precipitation or immune-depletion approaches 
(Markova et al 2005). 
 
The cysteinyl-labeling assay uses two alkylating agents that are used to differentially 
label reduced and oxidized PTP active sites. In brief, reduced cysteines in PTPs are 
blocked with an alkylating agent, whereas the oxidized PTPs - after exposure to 
reducing agents - are labeled with a biotin-coupled sulfhydryl-reactive probe and 
thereafter recovered by a streptavidin-pull-down procedure, SDS-PAGE and 
immunoblotting (Boivin et al 2008).  
 
In oxoMRM (multiple reaction monitoring) non-oxidized cysteines are differentiated 
from reduced cysteines through labeling with two different forms of N-ethylmalemide 
(NEM) (Held et al 2010). First, non-oxidized cysteines are labeled with un-tagged NEM. 
This is followed by a reduction step and a second labeling step using isotope tagged-
NEM. After immuno-precipitation and trypsin cleavage the peptides are separated 
with high-performance liquid chromatography and detected with mass spectrometry. 
Due to its design, the method will also identify irreversibly oxidized cysteines. In its 
present format the assay still depends on availability of specific PTP antibodies. 
Furthermore, early applications have indicated that different PTPs will display 
variations in susceptibility to trypsin cleavage which introduces another confounding 
factor. 
 
When discussing PTP oxidation it should be mentioned that this term commonly 
remains vaguely used. Many PTP oxidation assays that are used do not describe the 
actual oxidation of the PTP but rather the inactivation of the PTP activity or inability to 
bind to alkylating agents. A decreased activity or less binding to alkylating agents could 
also depend on other inactivating factors such as nitrosylation. If evidence for 
reversible PTP oxidation is warranted methods involving antibody based detection of 
oxidized PTPs or identification with mass spectrometry is to prefer. Next best is 
activity based assays, especially if used with and without reducing agents. Analyses of 
phosphorylation or activation state of different signaling pathways downstream of the 
oxidized PTP are also a good complement. Depletion of different ROS producing or 
ROS scavenging enzymes can increase or decrease PTP oxidation, respectively, and 
can be a valuable tool to achieve information about biological significance of PTP 
oxidation. Finally, depletion of specific PTPs might also help to identify PTPs involved 
in different settings. 
 
1.5 TYROSINE PHOSPHATASES AND CANCER  
Cancer is the general name for many diseases with the common feature of 
deregulated cell signaling. PTPs are normally occurring as negative regulators of cell 
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signaling and are therefore predicted to be involved in tumor progression by loss of 
function. However, increasing evidence predicts that PTPs can also have oncogenic 
functions (Julien et al 2011).  
 
1.5.1 PTPs as tumor suppressors 
Different approaches have been used to study the role of PTPs in cancer. Wang et al 
performed a systematic sequencing of colorectal cancers to search for mutations in 
PTPs. Screening of 18 colorectal cancers for mutations in all PTPs revealed that six of 
the PTPs had somatically derived mutations. These six PTP genes were analyzed in an 
additional 157 colorectal cancers where 77 different mutations were found, meaning 
that 26% of the tumors had one or more mutation(s). When the same genes were 
examined in other tumor types mutations were found in some cancer types, whereas 
others were unaffected. The predicted outcome from the 15 mutations was loss of 
PTP expression or loss of PTP activity. The mutations in the most frequently mutated 
PTP, the PTPRT (coding for PTPρ), were further analyzed and were also found to have 
decreased PTP activity (Wang et al 2004).  
Hyper-methylation of DNA can cause gene silencing and has been found in regulatory 
regions upstream of PTPRG, PTPRD, PTPRO, and PTPN13 genes in lymphoma, 
leukemia, glioblastoma and different carcinomas. This caused a loss in gene 
expression compared to normal tissue (Motiwala et al 2004, Motiwala et al 2007, van 
Doorn et al 2005, Wang and Dai 2007, Veeriah et al 2009, Yeh et al 2006). PTPN6 also 
displayed hyper-methylation and a subsequent loss of SHP-1 expression in lymphomas 
and leukemias (Koyama et al 2003, Oka et al 2002, Reddy et al 2005). 
 
PTPRT null mice were shown to have hyper-phosphorylated paxillin which ultimately 
led to increased Ras signaling. The PTPRT null mice were also shown to be more 
sensitive to develop carcinogen induced colon tumors than wild-type mice. (Zhao et al 
2010).  
 
DEP-1 has also been shown to have tumor suppressor functions in several studies. The 
first evidence was that different cancer cells decreased their growth rate after re-
expression of the DEP-1 protein. Other studies found loss of heterozygosity (LOH) in 
breast, colon and thyroid cancers (Ostman et al 2006). PTPRJ (encoding DEP-1) was 
found in the cancer susceptibility locus (Scc1) in a mice strain with increased colon 
cancer susceptibility. Further analyses in colon, lung and breast cancer samples 
revealed that PTPRJ had LOH in 49-78% of the cases (Ruivenkamp et al 2002). LOH of 
PTPRJ has also been found in meningiomas. In vitro studies revealed that the mobility 
of cells with loss of DEP-1 was increased. Tumors from DEP-1 depleted cells grew 
rapidly when transplanted in to mice and also displayed an increased invasion 
(Petermann et al 2010). 
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In addition, TC-PTP has been proved to be a tumor suppressor in T cell acute 
lymphoblastic leukemia due to deletions in the PTPN2 gene. The PTPN2 deletion was 
found in combination with the TLX1 transcription factor oncogene important for the 
activation of the mitotic checkpoint (Kleppe et al 2010). 
 
A recent study used a pool of shRNAs against all PTPs. They screened transformed 
cells and found PTPN12 as the top candidate. Quantitative proteomics revealed that 
69 proteins displayed increased phosphorylation with loss of PTPN12. The 69 
phosphorylated proteins were found to cluster in EGFR/HER2 pathways. Screening for 
mutations in breast cancer revealed that triple negative breast cancer had mutations 
in 4.8 % of the cases and that PTPN12 was lost in ~60% of the cases. In comparison, 
the groups with HER2 amplification or PR positive breast cancers displayed no PTPN12 
mutations or loss of PTPN12 protein. This indicated that PTPN12 is a tumor suppressor 
that is lost or inactivated in triple negative breast cancers (Sun et al 2011). 
 
1.5.2 PTPs as oncogenes 
Some PTPs have been found to promote, instead of inhibiting cell signaling. It is 
therefore not surprising that some PTPs are also oncogenic. This is best described in 
the case of SHP-2. The role of PTP1B in cancer appears more complicated and PTP1B 
has been described both as tumor suppressor and tumor promoter (Lessard et al 
2010).  
 
Two independent mouse models using activated ErbB2 (HER2) as promoter for 
mammary carcinogenesis showed that PTP1B null mice had a delayed onset of tumor 
formation (Bentires-Alj and Neel 2007, Julien et al 2007). The study performed by 
Bentires-Alj and Neel explained the positive role for PTP1B as an activator of the ERK 
pathway, however, only in the pre-malignant mammary tissue. Furthermore, if 
polyoma middle T were used to induce mammary tumors, PTP1B status did not affect 
tumor formation, indicating that PTP1B act only on specific signaling pathways 
(Bentires-Alj and Neel 2007). Julien et al found that PTP1B null tumors had decreased 
RAS-MAPK and Akt signaling. The positive role of PTP1B in the ErbB2 induced 
mammary tumor formation was also confirmed by the use of a small molecule 
inhibitor of PTP1B (Julien et al 2007). 
 
SHP-2 is a NRPTP that contains two SH2 domains, a PTP domain and a C-terminal tail 
with two tyrosine phosphorylation sites. It has been shown that SHP-2 requires both 
the PTP domain and the SH2 domains in order to carry out biological actions (Neel et 
al 2003). The crystal structure of SHP-2 revealed that the basal state of SHP-2 is a 
closed and inactive conformation in which the amino terminal SH2 domain is 
interacting with the PTP domain. Upon binding of the SH2 domain to pTyr, this closed 
structure is released and the catalytic activity is increased (Fig 6.) (Hof et al 1998).  
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Figure 6. Structure of SHP-2 
When SHP-2 binds to a phosphorylated substrates via the SH2 domains it opens up the structure and can 
dephsoporylate tyrosine phosphorylated substrates (S).  
 
SHP-2 has been shown to have a positive role in RTK signaling and to be required for 
cell transformation driven by a number of TKs, such as Bcr-Abl, EGFR, FGFR and Ret 
(Agazie et al 2003, Chen et al 2007, D'Alessio et al 2003, Zhan et al 2009). In a PDGF-
dependent glioma model, transformation was reverted if the binding sites for SHP-2 
and PI3K were deleted. Cell culture experiments confirmed that a SHP-2 inhibitor or 
SHP-2 shRNA could prevent transformation of the glioma cells (Liu et al 2011). 
 
Speculations on how SHP-2 mechanistically mediates the positive role in cell signaling 
and tumorigenesis have generated many suggestions, most of them involving 
activation of the Ras-MAPK pathway. One study revealed that SHP-2 mediates direct 
dephosphorylation of the binding site for Ras-Gap on the PDGF receptor and thereby 
induces Ras signaling (Klinghoffer and Kazlauskas 1995). Another study proposed a 
mechanism where SHP-2 dephosphorylate the binding site for Ras-Gap on Gab1 and 
thereby induce activation of Ras (Montagner et al 2005). Others suggested that SHP-2 
impairs C-terminal Src kinase (Csk)-mediated inhibition of Src, thereby also giving rise 
to Ras activation (Ren et al 2004, Zhang et al 2004). Finally, SHP-2 has been shown to 
dephosphorylate and thereby inactivate sprouty, an inhibitor of RTK signaling 
(Hanafusa et al 2004). 
 
Sequencing of PTPN11 (encoding SHP-2) revealed activating mutations in SHP-2 in one 
third of the cases of sporadic juvenile myelomonocytic leukaemia (JMML) and also, at 
lower frequencies, in myelodysplastic syndrome and acute myeloid leukemia (AML) 
(Loh et al 2004, Tartaglia et al 2003). Analyses of solid tumors displayed only a few 
cases with PTPN11 mutations (Bentires-Alj et al 2004). The disease-associated 
mutations were found to be clustered in the SH2 domains or in the catalytic site of 
SHP-2. Most of the mutations created an open protein conformation with a higher 
catalytic activity than wild type SHP-2 (Fig 6). Some of the mutations displayed a 
comparable activity to wild type in their basal state, but upon substrate binding 
increased their activity much more compared to wild type (Keilhack et al 2005, 
Tartaglia et al 2003).  
 
   25 
To gain further insight into the SHP-2 variants found in leukemia, primary bone 
marrow was transduced with SHP-2 constructs.  Transformation occurred after 
addition of the leukemia-variants of SHP-2, but only after a significant period of time. 
However, addition of cytokines caused hyper-activation of ERK, AKT and STAT5, 
suggesting that mutated SHP-2 works together with other mutations (Mohi et al 
2005). 
 
In breast cancer, mutations in SHP-2 are uncommon.  On the other hand, Gab2 which 
requires SHP-2 for transformation, is often amplified (Bentires-Alj et al 2006). Another 
cancer setting in which SHP-2 has been implied is Helicobacter Pylori-induced gastric 
cancer. During Helicobacter Pylori infection, the CagA protein is delivered to the 
gastric epithelial cells where it becomes tyrosine phosphorylated by Abl and Src 
kinases. The phosphorylated CagA protein can then bind to SHP-2 leading to the open 
and active conformation which in turn transforms the epithelial cells. Support for this 
model has also been provided using SHP-2 siRNA (Hatakeyama 2009). 
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2 PRESENT INVESTIGATION 
 
2.1 AIMS OF THE THESIS 
- To investigate the requirement for SHP-2 in PDGF-BB dependent autocrine 
transformation 
- To characterize PTP oxidation in different pathological settings that involve 
increased ROS production, such as hypoxia and restenosis 
- To explore the role of oxidized lipids in PTP oxidation and cell signaling  
-  
2.2 KEY FINDINGS 
2.2.1 Paper I 
Evaluation of the role of the protein tyrosine phosphatase SHP-2 in PDGF-BB 
autocrine transformation 
Since SHP-2 has been reported to act as a positive regulator of cell signaling 
downstream of different RTKs, we aimed to analyze the role of SHP-2 in PDGF 
dependent transformation. Tissue culture based transformation assays and xenograft 
experiments demonstrated that SHP-2 is required for PDGF-BB induced 
transformation of NIH3T3 fibroblasts. Downregulation of SHP-2 attenuated both Src 
activity and ERK phosphorylation. In addition, we found that SHP-2 repression impairs 
acidification of cell growth media.  
 
2.2.2 Paper II 
Hypoxia followed by re-oxygenation induces oxidation of tyrosine phosphatases 
Heart tissue ischemia, induced in the Langendorff model of ex vivo heart circulation, 
was found to induce oxidative inactivation of PTPs. Inactivation was detected both in 
the total pool of PTPs, and in immunoprecipitated SHP-2.  
 
In vitro experiments confirmed that hypoxia followed by reoxygenation caused PTP 
oxidation of receptor like PTPs and cytosolic PTPs. The elevated PTP oxidation was 
associated with a decreased PDGF receptor dephosphorylation and increased PDGF-
induced formation of lamellipodia structures. The latter was possible to attenuate 
with antioxidants. 
 
2.2.3 Paper III and V  
12/15-lipoxygenase-derived lipid peroxides control receptor tyrosine kinase 
signaling through oxidation of protein tyrosine phosphatases and Novel links 
between arachidonic acid metabolism, PTP oxidation and growth factor signaling 
GPx4 is an efficient scavenger of H2O2 and phospholipids in the cell. The aim was to 
explore the consequence of GPx4 depletion, and the concomitant increase in 
peroxidized lipids, on PTP oxidation.  
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GPx4 knock out cells displayed an increased level of peroxidized lipids and caused 
elevated PTP oxidation and inactivation, thus uncovering a novel mechanism for PTP 
oxidation. In vitro assays demonstrated that the peroxidized lipids were more potent 
than H2O2 with regard to the ability to oxidize PTPs. The PTP inactivation in the GPx4-/- 
cells occurred together with an increased ligand-independent PDGF receptor 
phosphorylation, reversible by addition of vitamin E, and PDGF receptor inhibitor-
sensitive lamellipodia formation.  
 
Addition of exogenous HpETE and AA to cells induced ligand independent PDGF 
receptor phosphorylation and AA-induced PTP oxidation was also detected. 12/15-
LOX null cells displayed reduced response to PDGF-BB with regard to phosphorylation 
and proliferation. These findings, obtained independent from the use of GPx4-/- cells, 
support the general notion of a crosstalk between AA metabolism and growth factor 
signaling.  
 
2.2.4 Paper IV 
 
Antioxidants relieve phosphatase inhibition and reduce PDGF signaling in cultured 
VSMCs and in restenosis 
Vascular disease involves activation of vascular smooth muscle cells (VSMCs). We 
aimed to investigate if inhibitory oxidation of PTPs is part of the increased activation 
of VSMC seen in restenosis. Neointima formation after vessel injury was found to be 
decreased in animals that received either of two antioxidants, N-acetylcysteine or 
tempol. Analysis of the injured vessels revealed that antioxidant treatment increased 
PTP activity and decreased PDGF receptor phosphorylation, compared to control 
treated animals. The protective effect of antioxidants on VSMCs could be confirmed in 
vitro using H2O2 as oxidizing agent. Interestingly, only N-acetylcysteine had a 
protective effect on PTP activity. In contrast, tempol, which had a protective effect 
against vessel injury in vivo had no effect on the PTP activity in cells. In vitro studies 
using VSMCs also showed that addition of antioxidant decreased PDGF induced 
migration and proliferation.  
 
2.3 FUTURE PERSPECTIVES  
We have demonstrated that SHP-2 is required for PDGF-BB dependent transformation 
of mouse fibroblasts. These studies should be extended to other PDGFR-dependent 
cancer models, e.g. primary cultures of glioblastoma cells or models of PDGF-
dependent GIST tumors. Further characterization of the pathways regulated by SHP-2 
in PDGF-dependent transformation is also warranted. SHP-2 displayed an interesting 
connection to acidification of the cell growth media. It would be interesting to further 
analyze if this phenotype is linked to the transformation-supportive roles of SHP-2. 
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The results from the hypoxia study showed that PTPs display oxidative inactivation 
after ischemia and hypoxia that were followed by reoxygenation. The finding that ERK 
phosphorylation and lamellipodia formation could be attenuated by the usage of 
antioxidant make it of interest to see if antioxidant mediated re-activation of PTPs 
could be a useful strategy in pathological settings that involve an increased ROS 
production. In addition, it would be most interesting to see if hypoxia-mediated PTP 
inactivation also occurs in hypoxic cancers and if this also leads to enhanced RTK 
signaling.  
 
The finding that knock-out of GPx4 created massive PTP oxidation in combination with 
the fact that 12/15-LOX knock-out cells did not respond to PDGF-BB indicates that a 
crosstalk occurs between the two pathways. One hypothesis that would be interesting 
to investigate is the possibility that GF stimulation possibly activates the 12/15-LOX 
enzyme, or blocks the GPx4 activity, to provide a feed forward loop for RTK activation. 
It would also be interesting to further investigate the PTP oxidation status in 12/15-
LOX cells. Concerning disease relevance it appears motivated to investigate if 
conditions associated with increased levels of peroxidized lipids also display increased 
PTP oxidation and enhanced RTK signaling. 
 
The restenosis study describes that ROS formation and PTP oxidation participate in 
the pathological processes of increased vessel thickening after injury. Future studies 
on the mechanisms for ROS production would be of high interest. It would also be 
interesting to obtain a more detailed description on which PTPs that are most 
important for PDGF-dependent and -independent processes involved in vessel 
remodeling after injury. 
 
Several methods have been used to detect PTP oxidation in this study. However, a 
need still remains for better methods to analyze oxidized PTPs in tissue sections. A 
potential method would be the proximity ligation assay with a format combining one 
binder against the PTP and one targeting the oxidized cysteine. Such an assay would 
make it possible to localize oxidized PTPs. Together with information about 
localization of ROS producers and ROS scavengers this should give better information 
about the role(s) for PTP oxidation in physiological and pathological settings. 
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4 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Kroppens signaler till dess celler är ett viktigt instrument för att styra om cellen ska 
dela sig, förflytta sig eller dö. Till cellen kommer signaler i form av proteiner, som 
kallas tillväxtfaktorer. Dessa binder till receptorer på cellens utsida. Aktivering av 
receptorer sker genom att fosforgrupper sätts på receptorn. Dessa fosfatgrupper kan 
också avlägsnas från receptorerna med hjälp av en klass proteiner som kallas 
tyrosinfosfataser (PTPs). 
 
Nettosignaleringen från cellyte-receptorerna bestäms alltså både av aktiviteten hos 
PTPs och mängden tillväxtfaktorer som når cellen. Ett genomgående tema i denna 
avhandling är analyser av hur PTPs kontrolleras och i vilken utsträckning störd PTP-
aktivitet bidrar till sjukdom.  
 
Flera sjukdomstillstånd, inklusive cancer och hjärtinfarkt, kännetecknas av syrebrist 
(hypoxi) i vävnaden. Vi har studerat hur hypoxi påverkar PTPs. Vi fann att hypoxi 
orsakade minskad aktivitet hos PTPs, vilket medförde att cellsignalering från cellyte-
receptorer ökade. Detta kunde påvisas både i hjärtvävnad och i celler odlade utanför 
kroppen. Dessa effekter kunde blockeras genom tillsatser av antioxidanter. 
 
Arteroskleros är ett tillstånd av förträngningar i kärl.  Normalt behandlas arteroskleros 
med ”ballongsprängningar” som öppnar upp kärlen och därigenom förbättrar 
blodcirkulationen. Ett vanligt problem efter detta ingrepp är att kärlen växer igen och 
att cirkulationen då åter blir nedsatt. Denna process kallas restenos och orsakas av 
överaktivitet hos en viss typ av cellyte-receptorer - PDGF receptorer - som stimulerar 
celldelning hos kärlväggsceller. Med hjälp av en restenos-djurmodell visades att 
restenos kunde minskas genom behandling med antioxidanter. En serie analyser 
antydde att dessa goda effekter av antioxidanter orsakades av en aktivering av PTPs, 
som i sin tur motverkade den sjukdomsframkallande PDGF receptor signaleringen. 
 
Peroxiderade lipider är en sorts molekyler som tidigare kopplats till vissa sjukdomar. I 
en studie användes en celltyp som producerar extra höga nivåer av peroxiderade 
lipider eftersom den saknar ett enzym – GPx4 – som normalt bryter ner dessa skadliga 
molekyler. Utan GPx4 ökade dramatiskt mängden inaktiverade PTPs och detta ledde 
till ökad cellsignalering. Kopplingen mellan peroxiderade lipider och PTPs hade tidigare 
inte visats och öppnar för en mängd studier för fortsatta undersökningar av kopplingar 
mellan peroxiderade lipider, PTP inaktivering och sjukdomsuppkomst. 
 
De flesta PTPs betraktas som ”bromsproteiner” för celldelning eftersom de stänger av 
cellyte-receptorer. Ett undantag från denna regel är SHP-2 som tidigare kopplats till 
olika tumörtyper. I en tumörmodell, som härmar tumörer med överaktiv PDGF 
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receptorsignalering kunde vi visa att cellernas tumöregenskaper blockerades om man 
förhindrade produktionen av SHP-2. Resultaten antyder att SHP-2-hämmare kan vara 
av nytta i vissa cancer-typer, t.ex. hjärntumörer, som är beroende av PDGF-
receptorsignalering. 
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